Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)

Trial Profile

A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plinabulin (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
  • Indications Neutropenia
  • Focus Registrational; Therapeutic Use
  • Acronyms Protective 2
  • Sponsors BeyondSpring Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2023 According to BeyondSpring Pharmaceuticals media release, the company withdrew its NDA submission for the CIN indication from China's National Medical Products Administration (NMPA) review. The Company will continue to communicate with the NMPA regarding its re-filing of the NDA for the CIN indication and plan to re-file the NDA by mid-2023.
    • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 01 Dec 2021 According to BeyondSpring Pharmaceuticals media release, the company has received a Complete Response Letter from the U.S FDA to NDA, indicating NDA application cannot be approved as results from Study 106 was not sufficiently robust to demonstrate benefit and that a second well controlled trial would be required to satisfy the substantial evidence requirement to support the CIN indication. The Company plans to request a meeting with the FDA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top